CRISPR Therapeutics AG (CRSP) EBITDA Margin Growth (5y) (2021 - 2026)
Powered by 
Analysis
CRISPR Therapeutics AG (CRSP) EBITDA Margin Growth (5y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.26 Bn | 9.41 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - |
| 3 | Iovance Biotherapeutics | 3.80 Bn | 3.50 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.04 Bn | 3.04 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.64 Bn | 2.64 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.98 Bn | 1.82 Bn | 56.40 Mn |
| 10 | Taysha Gene Therapies | 1.97 Bn | 1.97 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -123,651.00 |
| Mar 31, 2026 | 1.23 Mn |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | 4.76 Mn |
| Jun 30, 2025 | 15.77 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | -19,523.00 |
| Sep 30, 2024 | -1.84 Mn |
| Jun 30, 2024 | -1.20 Mn |
| Mar 31, 2024 | -1.31 Mn |
| Dec 31, 2023 | 3.94 Mn |
| Jun 30, 2023 | 329,099.00 |
| Mar 31, 2023 | 192,351.00 |
| Dec 31, 2022 | -219.24 Mn |
| Sep 30, 2022 | -19.30 Mn |
| Jun 30, 2022 | -11.54 Mn |
| Mar 31, 2022 | -1.80 Mn |
| Dec 31, 2021 | -4,975.00 |
| Sep 30, 2021 | -1.47 Mn |
| Jun 30, 2021 | 216,744.00 |